drugset
drugset / Trial / NCT03777865

Study To Describe The Safety Of 13-valent Pneumococcal Conjugate Vaccine In Children 6 To 17 Years Of Age In India

NCT03777865 ↗

Phase 4 Completed 100 enrolled Pfizer
NaSingle-groupOpen-labelPrevention

Summary

This is a Phase 4, open-label, single-arm, multicenter study in which subjects 6 to 17 years of age will receive 1 dose of 13vPnC.

Timeline

Start
2018-12-14
Primary completion
2019-04-17
Completion
2019-04-17

Drugs

EvaluationDrugModalityDoseRoute
Subject Prevnar 13 Vaccine 0.5 ml —

Indications

No indication recorded.